“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
INTERVIEW
Alzheimer’s Treatment at Crossroads? Top Expert on AD Research, Aducanumab and Its Implications - 1
Biogen’s closely watched Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first disease-modifying therapy and a definite game changer in the arena. How big is the potential target population in Japan…
To read the full story
Related Article
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
INTERVIEW
- From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
February 8, 2021
- Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
- “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
- Causes of NDMA Contamination Scandal Still under Investigation: NIHS Division of Drugs
January 27, 2020
- Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…